Absorb生物可吸收支架三年结局:ABSORB随机试验个体患者数据荟萃分析
该研究对4项ABSORB随机试验进行个体患者数据荟萃分析,共纳入3389例冠心病患者,随机接受Absorb BVS(n=2164)或钴铬依维莫司洗脱支架(n=1225)。结果显示,与钴铬依维莫司洗脱支架相比,BVS的3年靶病变失败率和器械血栓率均显著升高,且1至3年间的靶病变失败和器械血栓风险也更高。
要点
- BVS组3年靶病变失败率11.7% vs 8.1%(RR 1.38, 95%CI 1.10-1.73, P=0.006)。
- BVS组3年器械血栓率2.4% vs 0.6%(RR 3.71, 95%CI 1.70-8.11, P=0.001)。
- 1至3年间BVS靶病变失败和器械血栓风险均高于对照组。
核心结论
- 在ABSORB试验个体患者数据荟萃分析中,与依维莫司洗脱支架相比,BVS与1至3年间及累计3年随访的靶病变失败率和器械血栓率增加相关。
研究设计与样本
- 对4项ABSORB随机试验进行个体患者数据荟萃分析,共3389例冠心病患者随机分配至Absorb BVS组(n=2164)或钴铬依维莫司洗脱支架组(n=1225)。
主要发现
- BVS组3年靶病变失败率高于对照组(11.7% vs 8.1%;RR 1.38;95%CI 1.10-1.73;P=0.006)。
- BVS组3年靶血管心肌梗死率高于对照组(7.8% vs 4.2%;RR 1.72;95%CI 1.26-2.35;P=0.0006)。
- BVS组3年缺血驱动的靶病变血运重建率高于对照组(6.6% vs 4.4%;RR 1.44;95%CI 1.05-1.98;P=0.02)。
- 两组心源性死亡率相当(1.1% vs 1.1%;RR 0.93;95%CI 0.47-1.88;P=0.85)。
- BVS组3年器械血栓率高于对照组(2.4% vs 0.6%;RR 3.71;95%CI 1.70-8.11;P=0.001)。
临床怎么用
- 在冠心病介入治疗中,选择BVS需权衡其3年内较高的靶病变失败和器械血栓风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Absorb bioresorbable vascular scaffold (BVS) completely resorbs within 3 years after coronary artery implantation. The safety and effectiveness of BVS through this critical 3-year period have not been characterized. METHODS: We performed an individual-patient-data pooled meta-analysis of the 4 randomized ABSORB trials in which 3389 patients with coronary artery disease were randomly assigned to everolimus-eluting Absorb BVS (n=2164) or cobalt-chromium everolimus-eluting stents (n=1225). The primary efficacy outcome measure was target lesion failure (cardiac mortality, target vessel myocardial infarction, or ischemia-driven target lesion revascularization), and the primary safety outcome measure was device thrombosis. RESULTS: BVS compared with cobalt-chromium everolimus-eluting stents resulted in higher 3-year rates of target lesion failure (11.7% versus 8.1%; risk ratio [RR], 1.38; 95% confidence interval [CI], 1.10-1.73; P=0.006), driven by greater target vessel myocardial infarction (7.8% versus 4.2%; RR, 1.72; 95% CI, 1.26-2.35; P=0.0006) and ischemia-driven target lesion revascularization (6.6% versus 4.4%; RR, 1.44; 95% CI, 1.05-1.98; P=0.02), with comparable cardiac mortality (1.1% versus 1.1%; RR, 0.93; 95% CI, 0.47-1.88; P=0.85). Device thrombosis rates through 3 years were also higher with BVS (2.4% versus 0.6%; RR, 3.71; 95% CI, 1.70-8.11; P=0.001). Between 1 and 3 years, target lesion failure rates (6.1% versus 3.9%; P=0.02) and device thrombosis rates (1.1% versus 0.0%; P<0.0001) were higher with BVS than cobalt-chromium everolimus-eluting stents. CONCLUSIONS: In the present individual-patient-data pooled meta-analysis of the ABSORB trials, BVS was associated with increased rates of target lesion failure and device thrombosis between 1 and 3 years and cumulatively through 3 years of follow-up compared with everolimus-eluting stents. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov. Unique identifiers: NCT01751906, NCT01844284, NCT01923740, and NCT01425281.
引用
- Ali ZA, Gao R, Kimura T, et al. Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized Trials. Circulation. 2017. PMID: 29089314. doi:10.1161/CIRCULATIONAHA.117.031843
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。